A5006355538- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- Lung Cancer Diagnosis and Treatment
- Advanced Radiotherapy Techniques
- Lung Cancer Treatments and Mutations
- Radiomics and Machine Learning in Medical Imaging
- Cancer Genomics and Diagnostics
- Cancer, Lipids, and Metabolism
- Head and Neck Cancer Studies
- Cancer Immunotherapy and Biomarkers
- Colorectal and Anal Carcinomas
- Medical Imaging Techniques and Applications
- Cancer Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Gastric Cancer Management and Outcomes
- Lung Cancer Research Studies
- Multiple Myeloma Research and Treatments
- Advances in Oncology and Radiotherapy
- Hormonal and reproductive studies
- Renal cell carcinoma treatment
- Bladder and Urothelial Cancer Treatments
- Management of metastatic bone disease
- MRI in cancer diagnosis
- Radiation Therapy and Dosimetry
Rutgers, The State University of New Jersey
2016-2025
Johnson University
2021-2025
University of New Brunswick
2025
Rutgers Sexual and Reproductive Health and Rights
2025
Rutgers Cancer Institute of New Jersey
2015-2024
Johns Hopkins Medicine
2018-2022
Johns Hopkins University
2018-2022
Sidney Kimmel Comprehensive Cancer Center
2018-2022
Radiation Oncology Associates
2020
Johns Hopkins Hospital
2018-2020
Complete metastatic ablation of oligometastatic prostate cancer may provide an alternative to early initiation androgen deprivation therapy (ADT).To determine if stereotactic ablative radiotherapy (SABR) improves oncologic outcomes in men with cancer.The Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer (ORIOLE) phase 2 randomized study accrued participants from 3 US radiation treatment facilities affiliated a university hospital May 2016 March 2018 data...
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned co‐primary or secondary analyses are not yet available. Trial Updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported. STOMP and ORIOLE trial reports suggested metastasis-directed therapy (MDT) oligometastatic castration-sensitive...
Emerging data suggest that metastasis is a spectrum of disease burden rather than binary state, and local therapies, such as radiation, might improve outcomes in oligometastasis. However, current definitions oligometastasis are solely numerical. To characterize the somatic mutational landscape across metastatic castration-sensitive prostate cancer (mCSPC) to elucidate biological definition oligometastatic CSPC. This was retrospective study men with mCSPC who underwent clinical-grade...
In metastatic castration-sensitive prostate cancer (mCSPC), disease volume plays an integral role in guiding treatment recommendations, including selection of docetaxel therapy, metastasis-directed and radiation to the prostate. Although there are multiple definitions volume, they have commonly been studied context metastases detected via conventional imaging (CIM). One such numeric definition termed oligometastasis, is heavily dependent on sensitivity modality. We performed international...
Abstract Purpose: Prostate cancer is a heterogeneous disease ranging from indolent localized to metastatic castration-resistance. Efforts generate prognostic and predictive biomarkers understand trajectory beyond clinical variables alone include the Decipher Genomic Classifier (GC) Artera Multimodal AI (MMAI). Both are validated within prostate currently being evaluated in setting. It unknown if these reporting on similar biology through different means (gene expression vs digital pathology)...
Abstract Background: The trajectory of metastatic castration-sensitive prostate cancer varies based on disease presentation and biology. While proteomic profiling studies primary tissue have linked protein expression with progression prognosis, few explored biological changes after treatment their associations response. Therefore, we conducted patients oligometastatic (omCSPC) treated stereotactic ablative radiotherapy (SABR) or observation in the ORIOLE phase 2 randomized clinical trial...
Abstract Purpose Oligometastatic castration-sensitive prostate cancer (omCSPC) is a clinically and biologically heterogeneous disease. A multimodal artificial intelligence (MMAI) algorithm (ArteraAI Prostate Test), which incorporates digital histopathology clinical information, prognostic for outcomes in localized cancer. We hypothesized MMAI algorithms are also omCSPC correlate with tumor biology. Thus, we aimed to evaluate the association between score vector features (VF) genomics of...
231 Background: Prostate cancer is a heterogeneous disease ranging from indolent localized to metastatic castration-resistance. Efforts generate prognostic and predictive biomarkers understand trajectory beyond clinical variables alone include the Decipher Genomic Classifier (GC) Artera Multimodal AI (MMAI). Both are validated within prostate currently being evaluated in setting. It unknown if these reporting on similar biology through different means (gene expression vs digital pathology)...
140 Background: In the phase II EXTEND iADT omPC basket, MDT+iADT improved progression-free survival (PFS) vs iADT. Here we present primary results of cADT basket. We further report a pre-specified combined analysis with updated from basket and examine effects MDT on immunity. Methods: Patients 1 to 5 metastases were randomized 1:1 MDT+cADT (NCT03599765). consisted definitive local therapy. ADT +/- second-generation anti-androgens. The endpoint was per-protocol PFS, defined by biochemical...
TPS283 Background: Some patients with oligometastases may have the potential for long-term disease-free survival just aggressive local therapy as shown by randomized trials total consolidation of macroscopic metastases using metastasis-directed (MDT). Long-term outcomes pooled STOMP and ORIOLE in oligorecurrent metastatic castration-sensitive prostate cancer (omCSPC) demonstrated MDT improved progression free survival. However, men high-risk mutations, including pathogenic alterations ATM ,...
The use of radiation therapy (RT) in consolidating oligometastatic prostate cancer (OPCa) is a rapidly evolving treatment paradigm. We review our institutional experience using metastasis-directed the definitive management men with OPCa.Patients OPCa treated RT were included. Kaplan-Meier method and multivariable Cox regression analysis performed to assess biochemical progression-free survival (bPFS) time next intervention. Cumulative incidence functions used calculate rates local failure....
We sought to investigate whether enzalutamide (ENZA), without concurrent androgen deprivation therapy, increases freedom from prostate-specific antigen (PSA) progression (FFPP) when combined with salvage radiation therapy (SRT) in men recurrent prostate cancer after radical prostatectomy (RP).
•Synchronous metastatic CSPC is associated with lower AR activity than metachronous disease.•Patients synchronous derive a greater benefit to combination plus non AR-based therapy.•Clinical and biologic differences between metastasis are most prominent in low-volume disease. BackgroundMetastatic castration-sensitive prostate cancer (mCSPC) commonly classified into high- subgroups which have demonstrated differential biology, prognosis, response therapy. Timing of has similarly clinical...
The tumor suppressor gene SMAD4 (DPC4) is genetically inactivated in approximately half of pancreatic ductal adenocarcinomas (PDAs). We examined whether Smad4 status was associated with outcomes after adjuvant chemoradiation (CRT) for resected PDAs.Patients treated CRT were identified (N = 145). determined by immunolabeling and graded as intact or lost. Kaplan-Meier method multivariable competing risk analyses performed.On multivariate analysis, loss increased local recurrence (LR) (hazard...
PurposeMetastasis-directed therapy (MDT) is increasingly used in castration-sensitive oligometastatic prostate cancer because it prolongs progression-free survival (PFS) and androgen deprivation free survival. Here we describe patterns of recurrence identify modes progression after MDT using SABR.Methods MaterialsTwo hundred fifty-eight patients with (≤5 lesions at staging) were retrospectively identified from a multi-institutional database. Descriptive reported. Other outcomes including...